Loading
Launch Special: Analyst checkout is open at $29/mo (50% off regular price). Start checkout →
The U.S. International Trade Commission determined not to review an initial determination (Order No. 45) by the Chief ALJ granting an unopposed motion to amend the complaint and notice of investigation in Investigation No. 337-TA-1447 to reflect respondent Ascendis Pharma, Inc.'s corporate name change to Ascendis Pharma, LLC. The underlying investigation concerns certain drug products containing C-Type Natriuretic Peptide variants and components thereof.